Requirement for 1 or more repeat ablation · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).
1 finding from 1 review
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Requirement for 1 or more repeat ablation · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Outcomes at > 3 to 6 months after ablation · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality
The intervention showed no clear difference in all‐cause mortality (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular‐related mortality
The intervention showed no clear difference in cardiovascular‐related mortality (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause hospital admission (number of events) ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause hospital admission (number of participants with at least one event)
The intervention showed no clear difference in all‐cause hospital admission (number of participants with at least… (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular‐related hospital admission (number of events)
The intervention may leads to lower cardiovascular‐related hospital admission (number of events) (low certainty).
1 finding from 1 review
Intervention not reported
Cardiovascular‐related hospital admission (number of participants with at least one event)
The intervention showed no clear difference in cardiovascular‐related hospital admission (number of participants… (low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life
1 finding from 1 review
Intervention not reported
Health‐related quality of life
1 finding from 1 review
Intervention not reported
Adverse events ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular events · Adults without diabetes or CVD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · Adults without diabetes or CVD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Systolic blood pressure · Adults without diabetes or CVD
1 finding from 1 review